Implantable Neural Interface Device Enables Patients with Neuromuscular Disorders to Communicate Using Thoughts

The cofounders of Synchron, Dr. Thomas Oxley and Dr. Nicholas Opie, have developed an implantable brain-computer interface (BCI), the Synchron Switch, that allows individuals with severe paralysis to communicate and to control external digital devices using only their thoughts. In 2021, Synchron received approval from the Food and Drug Administration (FDA) to conduct human trials for the permanently implantable BCI. To date, 7 patients have received implants. One notable result reported involves a patient with amyotrophic lateral sclerosis (ALS) who used the implant to send a tweet using only their thoughts. 

The minimally invasive endovascular brain implant is surgically inserted via the jugular vein and incorporated into vasculature near the sensory and motor areas of the brain, where it converts brain signals into digital outputs. The endovascular implantation procedure prevents the need for open brain surgery, a significant challenge associated with other neural interfaces. The average post-procedure hospital stay for the Synchron Switch is only 48 hours.

The invention of this brain-computer interface offers hope for the millions of people with neurological conditions experiencing speech or mobility limitations. As Dr. Oxley notes, “It’s inspiring for the team seeing how much energy these people who are going through the most traumatic period of their lives are putting into this program.”

In recognition of their work, the two Australian researchers have been selected as finalists by the European Patent Office for the European Inventor Award 2023. Winners of the award will be announced on July 3, 2023.